Impaired fibrinolytic response to increased thrombin activation in Type 1 diabetes mellitus: Effects of the glycosaminoglycan Sulodexide

A. Ceriello, A. Quatraro, E. Marchi, M. Barbanti, D. Giugliano

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Data on fibrinolysis in diabtes mellitus are still unclear, as is the role of hyperglycaemia on this topic and the possibility of any therapeutic intervention. In this study we examined fibrinopeptide A, tissue plasminogen activator and plasminogen activator inhibitor plasma levels in Type 1 diabetic patients compared to matched healthy normal controls, and the effect of induced hyperglycaemia on these parameters. At the same time the effect of a glycosaminoglycan, Sulodexide, administration during hyperglycaemia was evaluated. Fibrinopeptide A and plasminogen activator inhibitor were increased while tissue plasminogen activator was decreased in Type 1 diabetic patients, in the basal state. Induced hyperglycaemia increases fibrinopeptide A formation and tissue plasminogen activator concentrations, while it decreases plasminogen activator inhibitor levels more in normal subjects than in diabetic patients. Sulodexide consistently reduces this phenomenon. This study shows an altered fibrinolytic response to increased thrombin activation in Type 1 diabetic patients and suggests that the administration of the glycosaminoglycan, Sulodexide, may help to reduce this phenomenon.

Original languageEnglish
Pages (from-to)225-229
Number of pages5
JournalDiabete et Metabolisme
Volume19
Issue number2
Publication statusPublished - 1993

Fingerprint

Fibrinopeptide A
Glycosaminoglycans
Type 1 Diabetes Mellitus
Plasminogen Inactivators
Thrombin
Hyperglycemia
Tissue Plasminogen Activator
Fibrinolysis
glucuronyl glucosamine glycan sulfate
Therapeutics

Keywords

  • fibrinolysis
  • glycosaminoglycan Sulodexide
  • hyperglycaemia

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Impaired fibrinolytic response to increased thrombin activation in Type 1 diabetes mellitus : Effects of the glycosaminoglycan Sulodexide. / Ceriello, A.; Quatraro, A.; Marchi, E.; Barbanti, M.; Giugliano, D.

In: Diabete et Metabolisme, Vol. 19, No. 2, 1993, p. 225-229.

Research output: Contribution to journalArticle

@article{02b35e6e9fe3434bbb41a1a3e3424b48,
title = "Impaired fibrinolytic response to increased thrombin activation in Type 1 diabetes mellitus: Effects of the glycosaminoglycan Sulodexide",
abstract = "Data on fibrinolysis in diabtes mellitus are still unclear, as is the role of hyperglycaemia on this topic and the possibility of any therapeutic intervention. In this study we examined fibrinopeptide A, tissue plasminogen activator and plasminogen activator inhibitor plasma levels in Type 1 diabetic patients compared to matched healthy normal controls, and the effect of induced hyperglycaemia on these parameters. At the same time the effect of a glycosaminoglycan, Sulodexide, administration during hyperglycaemia was evaluated. Fibrinopeptide A and plasminogen activator inhibitor were increased while tissue plasminogen activator was decreased in Type 1 diabetic patients, in the basal state. Induced hyperglycaemia increases fibrinopeptide A formation and tissue plasminogen activator concentrations, while it decreases plasminogen activator inhibitor levels more in normal subjects than in diabetic patients. Sulodexide consistently reduces this phenomenon. This study shows an altered fibrinolytic response to increased thrombin activation in Type 1 diabetic patients and suggests that the administration of the glycosaminoglycan, Sulodexide, may help to reduce this phenomenon.",
keywords = "fibrinolysis, glycosaminoglycan Sulodexide, hyperglycaemia",
author = "A. Ceriello and A. Quatraro and E. Marchi and M. Barbanti and D. Giugliano",
year = "1993",
language = "English",
volume = "19",
pages = "225--229",
journal = "Diabetes and Metabolism",
issn = "1262-3636",
publisher = "Elsevier Masson",
number = "2",

}

TY - JOUR

T1 - Impaired fibrinolytic response to increased thrombin activation in Type 1 diabetes mellitus

T2 - Effects of the glycosaminoglycan Sulodexide

AU - Ceriello, A.

AU - Quatraro, A.

AU - Marchi, E.

AU - Barbanti, M.

AU - Giugliano, D.

PY - 1993

Y1 - 1993

N2 - Data on fibrinolysis in diabtes mellitus are still unclear, as is the role of hyperglycaemia on this topic and the possibility of any therapeutic intervention. In this study we examined fibrinopeptide A, tissue plasminogen activator and plasminogen activator inhibitor plasma levels in Type 1 diabetic patients compared to matched healthy normal controls, and the effect of induced hyperglycaemia on these parameters. At the same time the effect of a glycosaminoglycan, Sulodexide, administration during hyperglycaemia was evaluated. Fibrinopeptide A and plasminogen activator inhibitor were increased while tissue plasminogen activator was decreased in Type 1 diabetic patients, in the basal state. Induced hyperglycaemia increases fibrinopeptide A formation and tissue plasminogen activator concentrations, while it decreases plasminogen activator inhibitor levels more in normal subjects than in diabetic patients. Sulodexide consistently reduces this phenomenon. This study shows an altered fibrinolytic response to increased thrombin activation in Type 1 diabetic patients and suggests that the administration of the glycosaminoglycan, Sulodexide, may help to reduce this phenomenon.

AB - Data on fibrinolysis in diabtes mellitus are still unclear, as is the role of hyperglycaemia on this topic and the possibility of any therapeutic intervention. In this study we examined fibrinopeptide A, tissue plasminogen activator and plasminogen activator inhibitor plasma levels in Type 1 diabetic patients compared to matched healthy normal controls, and the effect of induced hyperglycaemia on these parameters. At the same time the effect of a glycosaminoglycan, Sulodexide, administration during hyperglycaemia was evaluated. Fibrinopeptide A and plasminogen activator inhibitor were increased while tissue plasminogen activator was decreased in Type 1 diabetic patients, in the basal state. Induced hyperglycaemia increases fibrinopeptide A formation and tissue plasminogen activator concentrations, while it decreases plasminogen activator inhibitor levels more in normal subjects than in diabetic patients. Sulodexide consistently reduces this phenomenon. This study shows an altered fibrinolytic response to increased thrombin activation in Type 1 diabetic patients and suggests that the administration of the glycosaminoglycan, Sulodexide, may help to reduce this phenomenon.

KW - fibrinolysis

KW - glycosaminoglycan Sulodexide

KW - hyperglycaemia

UR - http://www.scopus.com/inward/record.url?scp=0027310669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027310669&partnerID=8YFLogxK

M3 - Article

C2 - 8339853

AN - SCOPUS:0027310669

VL - 19

SP - 225

EP - 229

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 2

ER -